Meritxell
Meritxell Gironella I Cos, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20120088687 | MicroRNAs (miRNA) as Biomarkers for the Identification of Familial and Non-Familial Colorectal Cancer - A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various groups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them. | 04-12-2012 |
Meritxell Gironella I Cos, Sant Cugat Del Valles ES
Patent application number | Description | Published |
---|---|---|
20130102487 | PLASMA MICRORNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER - The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer. | 04-25-2013 |
Meritxell Guino, York GB
Patent application number | Description | Published |
---|---|---|
20110108763 | CATALYST SYSTEMS FOR THE PRODUCTION OF ACIDS - Various embodiments of the invention herein described generally relate to novel processes for the production of aromatic acids by fixed bed catalytic oxidation of aromatic compounds carrying at least one oxidizable substituent group attached directly to the carbon atom of the corresponding aromatic nucleus. In an embodiment, a novel oxidation process of the present invention comprises the steps of: a) catalytically oxidizing, with an oxidation catalyst, a liquid phase aromatic acid precursor in the presence of a gaseous oxygen source; b) separating a finished product; c) purging the solvent and the oxidation catalyst; d) optionally recycling at least a portion of the solvent into the oxidation reactor; e) recovering at least a portion of the oxidation catalyst; f) recharging the at least a portion of the oxidation catalyst over a solid recharging catalyst bed; and (g) feeding a reactivated oxidation catalyst to the oxidation reactor. | 05-12-2011 |
Meritxell Lopez-Canet, Dusseldorf DE
Patent application number | Description | Published |
---|---|---|
20080275086 | Dpp-Iv Inhibitors - The invention relates to compounds of formula (I) | 11-06-2008 |
Meritxell Martí Gelabert, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20100099899 | METHOD FOR EXTRACTING INTERNAL LIPIDS FROM WOOL USING SUPERCRITICAL FLUIDS - A method for extracting internal lipids from wool that is substantially free of lanolin, comprising the use of a fluid under supercritical conditions and an agent that can change the polarity of said fluid, selected from methanol and/or ethanol, is disclosed. According to the operating conditions described, the temperature is between 40° C. and 120° C., and the pressure is between 120 bars and 330 bars. The polarity-changing agent represents between 3% and 15% expressed as volume/volume. The inventive method can be used to obtain internal lipids from wool, one of the most significant components of which are ceramides, which can be used in compositions intended to protect human skin against environmental damage. | 04-22-2010 |
Meritxell Martí Gelabert, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20100099899 | METHOD FOR EXTRACTING INTERNAL LIPIDS FROM WOOL USING SUPERCRITICAL FLUIDS - A method for extracting internal lipids from wool that is substantially free of lanolin, comprising the use of a fluid under supercritical conditions and an agent that can change the polarity of said fluid, selected from methanol and/or ethanol, is disclosed. According to the operating conditions described, the temperature is between 40° C. and 120° C., and the pressure is between 120 bars and 330 bars. The polarity-changing agent represents between 3% and 15% expressed as volume/volume. The inventive method can be used to obtain internal lipids from wool, one of the most significant components of which are ceramides, which can be used in compositions intended to protect human skin against environmental damage. | 04-22-2010 |
Meritxell Roseell, Stevenage GB
Patent application number | Description | Published |
---|---|---|
20150191696 | ADIPOSE TISSUE CELLS - The present invention relates to brown adipose tissue (BAT) cells derived from adult stern or progenitor cells, derived from adult white fat tissue (WAT), as well as to methods for deriving such cells. | 07-09-2015 |
Meritxell Roura Ferrer, Leioa ES
Patent application number | Description | Published |
---|---|---|
20150185205 | FLUORESCENT FUSION POLYPEPTIDE, BIOSENSOR COMPRISING SAID POLYPEPTIDE AND USES THEREOF - The present invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein: a. the membrane localization peptide is located at the N-terminus of the fluorescent fusion polypeptide and is physically bound, optionally through a linker, to the fluorescent peptide, which in turn is physically bound, optionally through a linker, to the second messenger transduction protein binding peptide; and b. the second messenger transduction protein binding peptide is physically bound, optionally through a linker, to the reticulum retention signal, which in turn is located at the C-terminus of the fluorescent fusion polypeptide. | 07-02-2015 |
Meritxell Rovira-Clusellas, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20140017207 | ISOLATION, EXPRESSION AND GUIDED DIFFERENTIATION OF SELF-RENEWING PROGENITOR CELLS FROM ADULT HUMAN PANCREAS - The present invention relates to the field of pancreatic progenitor cells. More specifically, the present invention provides methods for isolating self-renewing centroacinar and terminal ductal progenitors from adult human pancreas. In a specific embodiment, the method comprises the steps of (a) providing a population of pancreatic cells; and (b) selecting for high expression of CD133, EpCAM, and CD44 on the pancreatic cells to isolate self-renewing centroacinar and terminal ductal progenitors. | 01-16-2014 |
Meritxell Teixido, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20090286745 | INHIBITION OF ALPHA-SYNUCLEIN AGGREGATION - This invention relates to the inhibition of alpha-synuclein aggregation using peptidyl compounds which are retroenantiomers of the alpha-synuclein sequence, in particular retroenantiomers of sequences in the regions between residues 1 to 60 or residues 61 to 96. Peptidyl compounds of the invention may optionally be coupled to doperminergic targeting moieties and/or blood brain barrier transport moieties and may be useful in the treatment of alpha-synucleinopathies such as Parkinson's disease. | 11-19-2009 |
Meritxell Teixidó Turà, Sant Joan Despi ES
Patent application number | Description | Published |
---|---|---|
20100010011 | COMPOUNDS THAT ACT AS A VEHICLE FOR DELIVERY THROUGH THE BLOOD-BRAIN BARRIER AND CHARGE DELIVERY VEHICLE CONSTRUCTIONS - Compounds of formula (I), where R | 01-14-2010 |
Meritxell Teixidó Turà, Sant Joan Despi ES
Patent application number | Description | Published |
---|---|---|
20100010011 | COMPOUNDS THAT ACT AS A VEHICLE FOR DELIVERY THROUGH THE BLOOD-BRAIN BARRIER AND CHARGE DELIVERY VEHICLE CONSTRUCTIONS - Compounds of formula (I), where R | 01-14-2010 |
20150044140 | PROTEASE-RESISTANT COMPOUNDS USEFUL AS SHUTTLES THROUGH THE BLOOD-BRAIN BARRIER AND SHUTTLE-CARGO CONSTRUCTS - The peptides of formula (I) R | 02-12-2015 |